SHR-3167 not checked

Hengrui

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
6 active
9 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Type 2 Diabetes (2 trials), Diabetes Mellitus, Type 2 (2 trials), Type 2 Diabetes Mellitus, Diabetes Mellitus
Main trialPhase 3
“The purpose of this study is to evaluate efficacy and safety of SHR-3167 versus Insulin glargine in insulin-naive type 2 diabetes inadequately controlled on non-insulin anti-diabetic drugs. The hypothesis is that SHR-3167 is non-inferior to insulin glargine in the change of HbA1c from baseline after 26 weeks of treatment.”In the company’s words, NCT07920939 on ClinicalTrials.gov

Other drugs for Type 2 Diabetes

All 128 drugs for Type 2 Diabetes

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Oct 2027 Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Phase 3Not yet recruiting Jan 2028 A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin
Phase 2Active, not recruiting Feb 2026 A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Phase 2Active, not recruiting Dec 2026 A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents
Phase 1Recruiting Dec 2026 A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection
Phase 1Recruiting Mar 2027 A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
Phase 2Completed 22 Apr 2026 Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
Phase 1Unknown 25 Jan 2024 A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
Phase 1Completed 12 Jul 2024 To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SHR-3167

Following is part of Solo: you see every change to SHR-3167 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in